Introduction

Dementia with Lewy bodies (DLB) is often overlooked and misdiagnosed as
Alzheimer's Disease (AD) due to overlap in clinical presentation [1, 2] . Both DLB and AD are preceded by a prodromal period, generally denoted Mild Cognitive Impairment (MCI). It is generally acknowledged that pathology-specific treatments will need to target disease during the prodromal period. Therefore, it is important to identify patients during this phase. There is an extensive literature on the prodromal phase of AD, but limited literature on prodromal DLB.
Patients with fully manifest DLB have a characteristic neuropsychological and neuropsychiatric profile which is distinct from patients with AD [3] [4] [5] [6] . There is emerging evidence that even at the stage of MCI, DLB and AD patients have different neuropsychological profiles [7] . In a few early studies, patients with prodromal DLB more frequently exhibited fronto-executive, visuospatial and attentional deficits compared to those with prodromal AD. Prodromal AD patients more frequently had a prominent episodic memory deficit, which was present in only a minority of prodromal DLB patients [7] .
Fluctuations in cognition, spontaneous parkinsonism, and REM sleep behaviour disorder (RBD) were more frequently observed in prodromal DLB compared to prodromal AD in some studies [8] . However, the literature is less consistent regarding the core feature of visual hallucinations (VH) [7] .
The aim of the present study was to replicate the early findings in a large sample of patients from a non-academic setting. We therefore aimed to determine whether there are differences in the neuropsychological profile and clinical features of patients with prodromal DLB compared to prodromal AD and stable-MCI in an unselected sample of MCI cases.
Materials and Methods
Study design
The present study was a retrospective, longitudinal, observational study that used an unselected sample to test the hypothesis that patients with prodromal DLB will have a different cognitive and neuropsychiatric profile compared to patients with prodromal AD and stable-MCI.
Setting
The data used for the present study came from a Memory Clinic database. The Memory Clinic is part of the Old Age Psychiatry service in Essex, UK and provides specialized multidisciplinary assessments with emphasis on screening, early diagnosis and follow-up of patients at high risk of developing dementia. The clinic is part of the National Health Service, and it is based in a general hospital and covers inner city, suburban and rural areas with variable socioeconomic status. There is limited private provision of psychiatric diagnostic services in the UK and therefore the clinic benefits from near complete coverage of the local population.
Participants
A total of 1,847 new patients were seen at the Memory Clinic between 1994 and 2015. Of these, 559 patients (30.3%) had an initial diagnosis of MCI and were therefore considered for the present study (see figure 1) . Inclusion criteria were patients who had a diagnosis of MCI at initial assessment with a minimum of 12 months of follow-up.
All patients referred to the Memory Clinic underwent a comprehensive medical and psychiatric assessment and a physical examination by a doctor. Comprehensive neuropsychometric testing was performed by a psychologist. Following this, a multidisciplinary team of old-age psychiatrists, clinical psychologists and a memory clinic nurse assigned a consensus diagnosis according to published criteria [9] [10] [11] . At each yearly follow-up, the same process was repeated again assigning a consensus diagnosis which was recorded on the clinical database.
Ethical Review
The present study was reviewed and received approval from London -South East
Research Ethics Committee with reference number 15/LO/1752.
Data collected at baseline and yearly intervals
Data collected for each patient at baseline included age, gender, years of education, medical and psychiatric history, mental state examination and physical examination (including full neurological examination). Schedules performed included the Clinical Dementia Rating (CDR) [12] , and Modified Hachinski score (at baseline only) [13] .
The presence of DLB features was assessed and recorded at each visit, with support from the Clinician Assessment of Fluctuation Scale [14] , Mayo Sleep Questionnaire [15] , and the Unified Parkinson Disease Rating Scale part III (UPDRS) [16] . Patients with significant depressive or anxiety symptoms fulfilling ICD-10 diagnosis of a mood disorder or a neurotic, stress-related and somatoform disorder were excluded. In the very early stages of the study, before some of the above scales were available, a locally devised checklist was used to capture sleep disorders and fluctuations.
Cognitive testing included Mini-Mental State Examination (MMSE) [17] , the CAMCOG-R [18] , Wechsler Memory Scale (third edition abbreviated) Logical Memory Test (WMS LMT) [19] , and tests of executive function (Trail Making Tests A and B, category and letter fluency (FAS)). Additionally, a 10-item word recall task was used where scores reflect the mean of 3 tries to recall the list [20] .
Subdomains of the CAMCOG-R (maximum scores) are: Orientation (10) For the diagnosis of MCI, the Petersen et al criteria were used [11] . Patients with MCI were divided into amnestic and non-amnestic categories based on their performance on the WMS LMT [19] . At follow-up, established criteria were used for the diagnosis of clinically probable AD and DLB [9, 10] by a multidisciplinary consensus. Other diagnostic groups were excluded from the study, including patients with subjective cognitive impairment (subjective cognitive complaints but performance not below 1. 
Statistical Analysis
Statistical analyses were carried out using IBM SPSS version 19. We calculated baseline group characteristics for three groups of patients with MCI: those who remained stable (stable-MCI), those who declined to DLB (DLB-MCI) and those who declined to AD (AD-MCI). Data for continuous variables were not normally distributed therefore these were compared using Kruskal-Wallis tests. Mann-Whitney U-tests (two-tailed) were used to make pairwise comparisons only where the ANOVA was significant at p<.05. Chi-square or Fisher's exact tests were used to determine whether there were group differences on categorical variables. Where the 3-group test had a p<.05, pairwise analyses were performed. Of the 559 MCI patients, 428 had a minimum of one year follow-up. One hundred and sixty-four remained MCI (stable-MCI) while 107 progressed to AD and 21 to DLB at last follow-up. For the whole cohort, the mean follow-up was 2.8 years. One hundred and twenty-five patients were excluded due to alternative diagnoses at follow-up and 11 were excluded due to missing data (see Figure 1) .
Results
Of
The demographic details of the three groups are listed in Table 1 . The stable-MCI patients were younger and this reached statistical significance versus patients who converted to AD. As expected, UPDRS score was higher in the MCI patients who converted to DLB compared to patients who converted to AD as well as patients with stable-MCI. There was a greater proportion of males in the DLB-MCI group relative to the other two groups. The patients with stable-MCI had longer follow-up as they continued to be followed-up clinically whereas the patients progressing to dementia were referred to treatment clinics.
There was a greater proportion of patients with amnestic MCI subtype in the AD-MCI group relative to the other two groups. There was a higher frequency of visual hallucinations (VH), fluctuating cognition and REM sleep behaviour disorder (RBD) in the DLB-MCI group but this only reached significance for fluctuating cognition and RBD (see Table 1 ).
DLB-MCI patients performed significantly worse than AD-MCI patients and stable-MCI patients on letter fluency and the clock drawing test. DLB-MCI patients performed significantly better than AD-MCI patients on the new learning subscale of CAMCOG-R. For a full list of results on cognitive testing, see Tables 2 and 3. Scores for patients at time of conversion to dementia or last follow-up are shown in Tables 4-6 . Three patients with a DLB diagnosis had dopamine transporter SPECT imaging (all 3 cases had an abnormal scan, reduced uptake). No autopsies were available. During post-diagnostic follow-up, DLB patients developed further typical features which increased the certainty of the DLB diagnosis (95% had parkinsonism, 71% had visual hallucinations, 57% had fluctuations and 38% had RBD).
Discussion
In this large cohort, we found that already at the stage of MCI, there are clear differences in clinical features between patients who developed DLB, patients who progressed to AD, and those who remained stable. There are also clear differences on a number of cognitive tests. MCI patients who progressed to DLB were significantly more likely to have parkinsonism, fluctuating cognition and REM sleep behaviour disorder (RBD) even at this early stage. They also had more frequent visual hallucinations (VH), although this was only a trend. On cognitive testing, patients that later progressed to DLB performed worse at baseline on letter fluency and on a visuospatial task compared to patients that progressed to AD.
Overall, our results are in keeping with the findings of previous studies. Our finding that patients with prodromal DLB are more likely to have RBD, cognitive fluctuations or parkinsonism is in keeping with the existing literature [7, 8, 24, 25] . Some studies have found VH to be more common, but in our study this was only a trend at the stage of MCI.
This study strengthens the concept of prodromal DLB [26] and suggests that the core and suggestive features of DLB can be present a number of years before the manifestation of significant cognitive decline and functional impairment. The presence of these features in MCI patients should alert clinicians that this could be the early stages of DLB. Performing more in-depth cognitive assessment can also add support to the diagnosis of prodromal DLB. We have found impairment in visuospatial ability and this is consistent with the findings of previous studies [7, 8, 24, 25] . We have also found a significant difference in letter fluency relative to prodromal AD or stable-MCI which is consistent with the existing literature with the exception of one study [25] which did not find a difference.
The diagnosis of prodromal DLB is important. Any successful disease modifying treatment for DLB will have to be pathology-specific and will need to be introduced at the earliest possible stage of the disease course. This is also relevant to AD trials which depend on the study cohort having specific AD pathology. Contamination of prodromal AD cohorts by prodromal DLB could be a major obstacle to success.
The strengths of this study include that it is the largest cohort of its kind in Europe and the second largest worldwide [7] . Furthermore, it reports on an unselected incidence cohort from a secondary care service serving a local population with a clear catchment area and very limited alternative private provision. All patients underwent an identical comprehensive assessment at each follow-up and only a very small number of cases had missing data. All diagnoses were made by consensus in a multidisciplinary team and patients had a good length of follow-up.
This study had some limitations. Diagnosis was made according to the present diagnostic criteria based on clinical features only without the support of dopamine transporter scan in the majority of cases. No cases had polysomnography. The observed differences are at a group level and do not allow clinicians to accurately predict the outcome for individual patients. This will most probably require additional biomarkers to support the clinical diagnosis of prodromal DLB. Another limitation is the lack of neuropathological confirmation of diagnosis which will require a long-term follow-up. Lastly, only a small proportion of the initial MCI cohort converted to DLB although this is consistent with the lower incidence of DLB compared to AD.
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